PARD3B and colonic neoplasm: They found that Par3L peptides are more responsive to anti-tumor chemotherapy treatments and hypothesized that CRISPR/Cas9 could reduce adenosine monophosphate-activated protein kinase (AMPK) signaling transduction to preserve colon cancer cell survival by inactivating Par3L [23].